introduct
choulingdan
cld
laggerapterodonta
granul
ethnic
herbal
medicin
yunnan
provinc
china
cld
granul
use
treatment
inflammatori
condit
feverish
diseas
china
includ
season
influenza
evidencebas
medicin
ebm
clinic
studi
conduct
assess
efficaci
safeti
treatment
influenza
perform
ebm
clinic
trial
combin
western
chines
medicin
tradit
chines
medicin
tcm
evalu
system
evalu
efficaci
safeti
cld
granul
treatment
season
influenza
method
analysi
studi
design
multicentr
randomis
doubleblind
doublesimul
oseltamivircontrol
placebocontrol
paralleldesign
clinic
trial
elig
subject
alloc
satisfi
criteria
western
medicin
subject
randomis
receiv
cld
granul
oseltamivir
placebo
day
treatment
followup
treatment
record
symptom
sign
collect
pharyngealthroat
swab
serum
sampl
detect
viru
antibodi
time
syndrom
differenti
criteria
tcm
tongu
bodi
fur
tongu
type
puls
record
determin
doctor
western
chines
medicin
particip
instruct
compli
protocol
keep
daili
record
symptom
primari
secondari
outcom
safeti
indic
use
evalu
efficaci
safeti
cld
granul
treatment
season
influenza
base
western
chines
medicin
tcm
evalu
system
ethic
dissemin
cld
granul
clinic
trial
conduct
accord
declar
helsinki
good
clinic
practic
approv
ethic
committe
first
affili
hospit
guangzhou
medic
univers
particip
must
provid
written
inform
consent
result
obtain
dissemin
intern
medic
confer
peerreview
public
trial
registr
number
preresult
influenza
caus
highli
infecti
influenza
virus
includ
start
abrupt
onset
fever
nasorespiratori
disturb
malais
musculoskelet
ach
diseas
progress
swiftli
occur
primarili
spring
autumn
month
pandem
viru
caus
worldwid
outbreak
influenza
transmiss
highli
pathogen
avian
virus
human
first
report
hong
kong
sinc
avian
influenza
virus
global
infect
peopl
die
age
affect
mostli
year
mortal
rate
far
higher
sever
strength
limit
studi
first
evidencebas
medicin
clinic
trial
evalu
efficaci
chines
herbal
medicin
treatment
season
influenza
use
combin
western
tradit
chines
medicin
evalu
system
establish
evalu
system
futur
studi
chines
herbal
medicin
evidencebas
clinic
trial
use
syndrom
differenti
use
tradit
chines
medicin
increas
evid
clinic
use
choulingdan
granul
treat
season
influenza
lack
consensu
syndrom
differenti
criteria
tradit
chines
medicin
intern
open
access
acut
respiratori
syndrom
sar
emerg
infecti
diseas
virus
first
emerg
shanghai
anhui
provinc
china
end
march
fatal
rate
major
patient
critic
condit
given
high
infect
fatal
rate
influenza
urgent
need
improv
prevent
treatment
influenza
especi
use
drug
clinic
medicin
use
treatment
prevent
influenza
mainli
ion
channel
blocker
eg
amantadin
rimantadin
neuraminidas
na
inhibitor
eg
oseltamivir
zanamivir
amantadin
howev
prone
drug
resist
effect
influenza
viru
addit
treatment
effici
amantadin
lower
na
inhibitor
therefor
amantadin
recommend
routin
prevent
treatment
influenza
na
inhibitor
main
choic
clinic
treatment
influenza
viru
infect
specif
suppress
influenza
virus
b
intens
use
viral
strain
resist
toward
na
inhibitor
also
found
includ
pandem
viru
na
inhibitor
also
potenti
side
effect
nervou
system
compar
western
medicin
chines
herbal
medicin
wide
use
chines
clinic
regul
multipl
target
treatment
improv
immun
function
advantag
reliev
upper
respiratori
tract
symptom
consid
pandem
viru
virus
may
occur
futur
investig
potenti
use
chines
herbal
medicin
prevent
treatment
influenza
great
research
valu
tradit
chines
medicin
tcm
influenza
said
resembl
feng
wen
windheat
type
wenb
mean
feverish
diseas
practition
chines
medicin
believ
occurr
feng
wen
windheat
associ
season
climat
close
resembl
influenza
respiratori
ailment
diseas
preval
ancient
china
wen
bing
develop
highli
specialis
branch
tcm
trace
back
year
abnorm
climat
chang
facilit
epidem
respiratori
diseas
meanwhil
human
bodi
fail
adapt
lead
brain
centr
adjust
disord
decreas
diseas
resist
thu
increas
suscept
viral
invas
caus
preval
respiratori
diseas
accord
tradit
wen
bing
precept
progress
influenzalik
diseas
divid
four
stage
fever
develop
nasal
symptom
fever
chill
haemoptysi
modern
medicin
first
two
stage
may
view
symptom
usual
subsid
without
treatment
later
stage
repres
unusu
condit
bronchiti
lateonset
pneumonia
occur
excess
fever
regard
kind
toxin
tcm
china
herbal
medicin
clear
away
heat
toxic
materi
recommend
use
banlangen
jinyinhua
yuxingcao
one
herbal
medicin
clear
away
heat
toxic
materi
choulingdan
cld
laggera
pterodonta
famili
laggera
schbip
ex
hochst
wide
cultiv
yunnan
provinc
china
approv
list
yunnan
chines
herbal
medicin
kunm
common
folk
herbal
medicin
yunnan
materi
medic
antibacteri
antiinflammatori
clear
heattox
effect
root
whole
plant
wide
use
treat
cold
sore
throat
bronchiti
malaria
diseas
accord
previou
studi
research
group
cld
effect
influenza
vivo
vitro
mani
activ
fraction
isol
l
pterodonta
includ
fr
pterodont
acid
wide
spectrum
antiinfluenza
viru
activ
sesquiterpenoid
l
pterodonta
also
prevent
increas
cytokin
chemokin
express
l
pterodonta
may
use
develop
innov
antivir
drug
studi
perform
investig
mechan
action
detail
current
varieti
commerci
avail
cld
prepar
chines
patent
medicin
contain
cld
main
ingredi
china
observ
clinic
studi
conduct
second
affili
hospit
kunm
medic
univers
outbreak
influenza
viru
found
compar
clinic
cur
effect
yinqiao
jiedu
tablet
chines
patent
medicin
contain
cld
better
antivir
effect
effect
reduc
number
virus
respiratori
secret
acceler
viru
clearanc
addit
good
efficaci
safeti
quick
relief
fever
sore
throat
symptom
without
advers
reaction
shown
treatment
children
influenza
howev
lack
evidencebas
medicin
ebm
clinic
studi
evalu
efficaci
safeti
cld
granul
treatment
season
influenza
addit
previou
clinic
studi
focus
western
medic
method
evalu
efficaci
chines
herbal
medicin
suit
lack
matur
tcm
evalu
system
develop
cld
target
drug
less
side
effect
wide
use
prevent
treatment
influenza
indepth
studi
need
conduct
studi
multicentr
randomis
doubleblind
doublesimul
approach
use
hope
clinic
efficaci
cld
treatment
influenza
fulli
verifi
highest
level
clinic
trial
empir
evid
treatment
cld
posit
outcom
influenza
viru
infect
yet
evidencebas
clinic
trial
conduct
seek
gain
indepth
understand
efficaci
safeti
cld
use
influenza
infect
ebm
clinic
studi
addit
investig
whether
cld
granul
differ
therapeut
effect
differ
tcm
open
access
syndrom
differenti
compar
symptom
treatment
studi
design
multicentr
randomis
doubleblind
doublesimul
oseltamivircontrol
placebocontrol
paralleldesign
clinic
trial
elig
subject
alloc
randomli
three
group
ratio
oseltamivir
treatment
posit
control
cld
treatment
test
placebo
group
randomis
alloc
number
provid
thirdparti
unit
chines
evidencebas
medicin
center
west
china
hospit
sichuan
univers
china
base
current
evid
oseltamivir
treat
season
influenza
patient
diseas
burden
also
referenc
cours
treatment
anoth
chines
prescript
lianhuaqingwen
capsul
treat
influenza
particip
group
receiv
treatment
day
observ
day
follow
research
interview
day
treatment
studi
flowchart
shown
figur
followup
period
specif
item
collect
see
onlin
supplementari
appendix
remedi
period
particip
requir
regist
daili
record
symptom
symptom
base
western
medicin
case
report
form
crf
tabl
tcm
syndrom
differenti
base
tcm
tabl
record
pharyngealthroat
swab
upper
respiratori
tract
use
rtpcr
cultiv
influenza
viru
blood
sampl
use
test
influenza
viru
antibodi
figur
studi
flowchart
particip
meet
inclus
criteria
recruit
assign
randomli
three
differ
group
particip
accept
treatment
followup
period
observ
data
collect
evalu
treatment
efficaci
safeti
choulingdan
cld
auc
area
curv
crf
case
report
form
tcm
tradit
chines
medicin
tabl
continu
open
access
subject
screen
select
pharyngealthroat
swab
outpati
probabl
influenza
taken
first
detect
influenza
viru
via
pointofcar
test
kit
enrol
patient
posit
result
refer
inclus
exclus
criteria
shown
patient
enrol
meet
inclus
criteria
enrol
one
exclus
criteria
patient
remov
trial
meet
one
reject
criteria
termin
standard
enrol
particip
requir
provid
written
inform
consent
cooper
doctor
treatment
cooper
followup
provid
inform
beyond
remit
ethic
approv
patient
compli
remov
studi
period
pharyngealthroat
swab
blood
sampl
collect
particip
particip
also
distinguish
accord
tcm
syndrom
differenti
criteria
describ
studi
design
enrol
patient
six
unit
six
unit
includ
main
central
unit
first
affili
hospit
guangzhou
medic
univers
subcentr
unit
outpati
depart
guangdong
provinc
tradit
chines
medic
hospit
second
affili
hospit
kunm
medic
univers
first
peopl
hospit
yulin
citi
shaanxi
provinc
second
peopl
hospit
liwan
district
guangzhou
first
peopl
hospit
yunnan
provinc
unit
charg
specif
respons
studi
includ
enrol
patient
collect
specimen
data
viru
antibodi
detect
perform
laboratori
first
affili
hospit
guangzhou
medic
univers
clinic
virolog
divis
nation
key
laboratori
respiratori
diseas
guangzhou
china
data
analysi
carri
chines
evidencebas
medicin
center
thirdparti
unit
ensur
safeti
patient
blind
studi
design
data
qualiti
adher
studi
protocol
personnel
particip
directli
studi
adequ
train
follow
guidelin
good
clinic
practic
gcp
male
femal
patient
influenza
age
year
elig
studi
particip
provid
meet
follow
inclus
criteria
confirm
infect
influenza
influenza
b
viru
accord
realtim
pcr
viral
cultur
ii
axillari
temperatur
least
two
constitut
symptom
headach
chill
myalgia
fatigu
one
respiratori
symptom
cough
sore
throat
rhiniti
iii
ill
onset
within
hour
iv
sign
written
inform
consent
exclus
criteria
detail
tabl
particip
meet
reject
criteria
remov
data
includ
final
statist
analysi
howev
termin
standard
relat
enrol
patient
may
termin
remedi
period
data
patient
includ
final
statist
analysi
reject
criteria
termin
standard
detail
tabl
tcm
syndrom
differenti
criteria
cold
heat
two
principl
use
differenti
natur
diseas
tcm
cold
heat
caus
diseas
reflect
defici
excess
yin
yang
bodi
yin
excess
yang
defici
lead
cold
syndrom
yang
excess
yin
defici
lead
heat
syndrom
distinguish
factor
cold
heat
syndrom
shown
tabl
base
detail
symptom
shown
tabl
patient
divid
two
type
accord
two
tcm
practition
inform
consent
doctor
confirm
patient
satisfi
particip
criteria
consent
given
subsequ
discuss
patient
medic
offic
trial
team
patient
given
suffici
time
opinion
fulli
consid
trial
entri
ask
question
investig
written
inform
consent
form
sign
patient
will
particip
clinic
trial
patient
age
year
hisher
parent
also
inform
detail
trial
child
parent
sign
inform
consent
child
may
particip
trial
materi
consent
obtain
specif
address
collect
biolog
sampl
futur
use
serum
plasma
specimen
randomis
follow
inform
consent
patient
randomli
assign
ratio
three
group
oseltamivir
treatment
posit
control
cld
treatment
test
placebo
group
randomis
alloc
number
provid
chines
evidencedbas
medicin
center
randomis
stratifi
trial
centr
differ
region
randomis
perform
use
sa
softwar
gener
random
number
correspond
drug
case
alloc
scheme
enclos
opaqu
envelop
trial
doctor
distribut
drug
order
origin
arrang
blind
randomis
system
implement
manag
chines
evidencedbas
medicin
center
randomis
code
maintain
specif
appoint
independ
custodian
research
particip
inspector
data
entrant
blind
drug
randomli
code
accord
randomis
protocol
code
number
uniqu
identif
code
particip
accord
order
patient
visit
randomli
divid
differ
group
test
drug
control
drug
open
access
placebo
dosag
form
dose
doubleblind
method
use
prepar
drug
requir
uniform
packag
group
use
drug
label
data
lock
perform
crf
data
review
duplic
data
entri
verif
outlier
data
collect
process
issu
question
form
research
q
complet
blind
review
meet
particip
must
satisfi
follow
criteria
studi
entri
confirm
infect
influenza
influenza
b
viru
accord
realtim
pcr
viral
cultur
age
year
axillari
least
two
constitut
symptom
headach
chill
myalgia
fatigu
one
respiratori
symptom
cough
sore
throat
rhiniti
ill
onset
within
hour
grant
written
inform
consent
exclus
criteria
particip
enrol
one
follow
exclus
criteria
age
year
year
confirm
bronchiti
pneumonia
pleural
effus
interstiti
lung
diseas
via
chest
imag
radiograph
ct
routin
screen
blood
test
leucocyt
read
l
neutrophil
suppur
tonsil
purul
sputum
underl
primari
disord
includ
haematolog
diseas
chronic
obstruct
pulmonari
diseas
forc
expiratori
volum
forc
vital
capac
valu
respiratori
failur
right
heart
failur
hepat
diseas
alanin
aminotransferas
aspart
upper
limit
normal
renal
diseas
serum
creatinin
mgdl
chronic
congest
heart
failur
new
york
heart
associ
class
iii
iv
previou
use
antivir
drug
amantadin
rimantadin
zanamivir
oseltamivir
phosphat
diseas
onset
studi
enrol
use
tradit
chines
herbal
medicin
proprietari
chines
medicin
administr
choulingdan
granul
within
week
diseas
onset
allergi
studi
medic
women
pregnant
may
possibl
becom
pregnant
lactat
posit
urin
pregnanc
test
bodi
mass
kgm
immunodefici
malign
tumour
aid
taken
immun
inhibitor
last
month
organ
bonemarrow
transplant
suspicion
histori
alcoholdrug
abus
particip
anoth
clinic
trial
month
studi
randomis
acut
respiratori
infect
otiti
nasosinus
week
studi
enrol
vaccin
influenza
vaccin
within
month
reason
investig
discret
particip
remov
meet
one
reject
criteria
meet
inclus
exclus
criteria
withdraw
inform
consent
withdraw
inform
consent
followup
data
obtain
admiss
seriou
violat
programm
ie
patient
receiv
therapi
simultan
efficaci
determin
termin
standard
particip
termin
meet
one
termin
standard
patient
ill
becom
sever
sever
meet
one
follow
criteria
persist
high
fever
day
ii
sever
cough
purul
sputum
bloodi
sputum
pectoralgia
iii
rapid
breath
troubl
breath
lip
cyanosi
iv
altern
conscious
ie
drowsi
restless
convuls
v
sever
vomit
diarrhoea
dehydr
vi
imag
confirm
sign
pneumonia
vii
rapid
elev
level
myocardi
enzym
creatin
kinas
creatin
kinas
isoenzym
viii
underli
diseas
exacerb
significantli
death
includ
death
caus
influenza
caus
death
antibiot
treatment
requir
bacteri
pneumonia
tympan
nasosinus
secondari
influenza
seriou
advers
event
occur
health
reason
open
access
pioneer
investig
pi
biostatist
expert
sponsor
requir
present
three
parti
make
blind
review
resolut
signatur
three
parti
unblind
carri
statist
unblind
data
complet
biostatist
expert
issu
statist
report
pi
compil
summari
report
base
statist
report
choulingdan
granul
treatment
test
group
patient
group
administ
four
bag
cld
granul
gper
bag
half
hour
meal
three
time
daili
day
taken
analog
oseltamivir
capsul
twice
daili
day
oseltamivir
treatment
posit
group
patient
group
administ
one
oseltamivir
capsul
mgper
capsul
half
hour
meal
twice
daili
day
four
bag
analog
cld
granul
three
time
daili
day
patient
group
administ
four
bag
cldanalog
granul
half
hour
meal
three
time
day
well
analog
oseltamivir
phosphat
capsul
twice
day
day
cld
granul
cldanalog
granul
analog
oseltamivir
phosphat
capsul
manufactur
panlongyunhai
pharmaceut
certif
number
good
manufactur
practic
gmp
pharmaceut
product
oseltamivir
capsul
bought
shanghai
roch
pharmaceut
certif
number
gmp
pharmaceut
product
qualiti
control
method
cld
granul
highperform
liquid
chromatographi
method
use
qualiti
control
cld
granul
chromatograph
condit
system
suitabl
test
octadecylsilanebond
silica
gel
use
filler
formic
acid
solut
use
mobil
phase
detect
wavelength
nm
number
theoret
plate
accord
calcul
artemitin
prepar
refer
solut
take
appropri
amount
artemitin
refer
substanc
accur
weigh
add
methanol
make
solut
contain
artemitin
per
ml
prepar
test
solut
take
one
pack
cld
granul
content
uniform
satisfi
pharmacopoeia
requir
g
accur
weigh
mill
place
conic
flask
precis
add
ml
methanol
seal
weigh
heat
reflux
hour
let
cool
weigh
make
lost
weight
methanol
shake
filter
take
subsequ
filtrat
assay
separ
draw
refer
solut
test
solut
inject
liquid
chromatograph
measur
result
qualifi
product
contain
mg
artemitin
c
h
per
pack
placebo
contain
excipi
sucros
lactos
dextrin
posit
test
drug
contain
dosag
regimen
strictli
follow
usual
dosag
direct
treatment
cld
granul
oseltamivir
capsul
placebo
match
cld
granul
oseltamivir
capsul
tast
colour
accord
requir
doubleblind
doublesimul
test
drug
within
trial
period
pack
panlongyunhai
pharmaceut
drug
count
sort
third
parti
chines
evidencedbas
medicin
center
drug
within
expir
date
treatment
may
taken
particip
follow
symptom
axillari
temperatur
last
hour
reduc
physic
cool
bodi
temperatur
headach
myalgia
score
point
symptomat
treatment
measur
follow
fever
acetaminophen
b
sever
cough
white
phlegm
bisolvon
c
mild
asthmat
symptom
longact
theophyllin
drug
may
use
detail
inform
drug
use
regist
crf
rescu
medicin
provid
panlongyunhai
pharmaceut
doctor
issu
drug
accord
patient
need
event
symptom
patient
toler
sever
headach
myalgia
attend
doctor
treat
patient
accord
actual
situat
decid
whether
termin
experi
cost
provid
research
team
investig
instruct
particip
record
actual
dose
patient
diari
base
diari
investig
evalu
subject
adher
intervent
follow
four
level
record
open
access
result
case
report
form
followup
take
prescrib
medic
basic
prescrib
medic
dose
programm
take
medic
prescrib
halftim
almost
medic
half
time
subject
taken
prescrib
medic
sure
indic
reason
data
collect
data
collect
daili
record
symptom
record
particip
crf
tabl
tcm
syndrom
score
record
medic
offic
trial
team
result
laboratori
first
affili
hospit
guangzhou
medic
univers
clinic
virolog
divis
nation
key
laboratori
respiratori
diseas
guangzhou
china
data
entri
manag
respons
assign
data
manag
establish
databas
verif
procedur
two
specialis
train
keyboard
oper
input
confirm
data
check
crf
identifi
entri
error
correct
input
data
exactli
crf
queri
crf
commun
research
data
queri
form
data
queri
form
must
process
sign
date
time
research
resolv
data
question
must
return
data
manag
revis
verifi
data
accord
feedback
correspondingli
updat
databas
necessari
data
question
form
queri
databas
lock
confirm
accuraci
establish
databas
blind
review
lock
data
chang
data
revis
need
lock
offici
statement
jointli
sign
sponsor
main
research
experiment
project
manag
statistician
data
manag
must
provid
addit
revis
perform
statist
analysi
crowd
divis
unblind
data
data
review
case
assess
confirm
intenttotreat
popul
modifi
intenttotreat
popul
mittp
perprotocol
popul
ppp
safeti
analysi
popul
sap
decis
approv
data
manag
studi
promot
research
end
unblind
lock
databas
efficaci
evalu
base
patient
symptom
bodi
temperatur
viru
inspect
primari
outcom
time
allevi
influenzalik
symptom
fever
stuffi
nose
run
nose
sore
throat
cough
myalgia
fatigu
headach
chill
sweat
measur
hour
allevi
mean
influenzalik
symptom
score
mild
state
stabl
hour
secondari
end
point
consist
seven
aspect
time
defervesc
measur
hour
bodi
temperatur
drop
defin
defervesc
condit
maintain
hour
defin
complet
defervesc
ii
area
curv
auc
analysi
nine
influenzalik
symptom
score
provid
indic
diseas
sever
auc
calcul
product
daili
symptom
score
multipli
durat
ill
iii
treatment
efficaci
differ
tcm
syndrom
assess
tcm
syndrom
score
iv
time
initi
treatment
return
normal
life
work
school
sustain
hour
v
durat
viral
shed
number
day
start
treatment
first
viru
detect
neg
viral
cultur
pcr
result
neg
subsequ
viru
detect
result
neg
vi
frequenc
acetaminophen
use
vii
incid
complic
includ
otiti
media
sinus
acut
parot
suppur
tonsil
bronchiti
pneumonia
rey
syndrom
central
nervou
system
diseas
encephalopathi
enceph
mening
myeliti
multipl
neuriti
myocard
pericard
acut
myositi
poison
shock
syndrom
indic
vital
sign
cardiopulmonari
sign
electrocardiographi
clinic
laboratori
test
biochemistri
haematolog
urin
examin
compar
treatment
assess
safeti
addit
research
interview
keep
touch
particip
monitor
safeti
advers
event
vital
sign
symptom
diseas
laboratori
paramet
patient
occur
enter
clinic
trial
record
committe
causeandeffect
relationship
advers
event
studi
drug
determin
classif
shown
tabl
patient
seriou
advers
event
necessari
know
specif
situat
medic
unblind
permiss
obtain
consent
main
investig
emerg
letter
read
case
treat
shed
sampl
size
calcul
elig
subject
age
year
accept
recommend
influenzalik
ill
ili
use
basi
influenza
surveil
patient
present
acut
cough
fever
clinician
must
highli
vigil
test
infect
caus
influenza
viru
gener
rate
ili
case
lead
clinic
diagnosi
influenza
infect
approxim
higher
clinic
diagnos
exampl
acut
infect
upper
respiratori
tract
select
adult
patient
ili
inclus
studi
furthermor
trial
confirmatori
studi
treatment
influenza
cld
granul
patient
randomli
assign
three
group
posit
group
test
group
placebo
group
trial
number
sampl
case
estim
base
test
hypothesi
test
group
superior
placebo
group
test
group
inferior
posit
control
group
main
index
treatment
effect
period
time
subsid
symptom
hour
report
averag
period
time
remiss
symptom
placebo
group
day
hour
trial
requir
averag
time
symptomat
remiss
test
group
least
hour
shorter
placebo
group
mean
permiss
error
superior
trial
hour
order
consid
clinic
signific
mean
time
symptomat
remiss
posit
group
must
hour
compar
placebo
group
mean
superior
trial
within
hour
tabl
base
data
sa
softwar
use
estim
sampl
size
requir
oneway
analysi
varianc
calcul
result
design
three
parallel
group
tabl
achiev
adequ
particip
enrol
patient
recruit
clinic
trial
mainli
local
advertis
particip
receiv
financi
compens
finish
entir
treatment
patient
drop
payment
prorat
length
time
stay
studi
payment
made
studi
would
complet
clinic
data
manag
analys
third
parti
chines
evidencedbas
medicin
center
data
manag
analysi
use
spss
ibm
armonk
new
york
usa
sa
sa
institut
cari
north
carolina
usa
respect
intenttotreat
popul
case
express
accept
trial
inform
consent
randomis
studi
drug
use
least
intervent
effect
outcom
record
least
use
experiment
drug
reason
relationship
time
similar
pharmacolog
effect
drug
experiment
drug
well
known
difficult
identifi
caus
owe
diseas
explan
use
experiment
drug
reason
relationship
time
advers
event
may
caus
diseas
explan
connect
time
test
drug
easi
explain
diseas
main
symptom
diseas
unrel
connect
time
test
drug
advers
event
definit
caus
reason
test
drug
open
access
ppp
includ
case
meet
inclus
criteria
full
accord
test
programm
violat
protocol
slightli
complet
trial
complet
crf
ppp
use
analys
main
indic
evalu
efficaci
examin
consist
result
mitt
randomis
studi
drug
taken
least
intervent
effect
safeti
evalu
data
record
least
experi
baselin
data
efficaci
analysi
analys
mittp
simultan
primari
efficaci
end
point
ppp
analysi
conclus
mainli
base
mitt
analysi
result
mittp
analysi
ppp
analysi
consist
credibl
conclus
increas
miss
data
last
observ
carryforward
locf
method
use
extrapol
data
sap
use
examin
laboratori
data
advers
event
advers
reaction
rate
advers
reaction
employ
sap
denomin
statist
analysi
plan
spss
sa
statist
softwar
use
ii
statist
infer
use
twosid
test
statist
signific
mean
p
ci
paramet
estim
use
ci
iii
efficaci
analys
locf
use
compens
case
inform
patient
record
treatment
last
observ
data
transfer
final
test
result
safeti
analysi
estim
miss
data
iv
comparison
dropout
rate
dropout
rate
caus
advers
event
undertaken
use
pearson
test
v
measur
data
given
mean
sd
ci
necessari
minimum
maximum
median
provid
pair
measur
data
also
use
demonstr
differ
mean
sd
nonparametr
method
median
mean
rank
provid
count
data
frequenc
distribut
correspond
percentag
level
data
given
frequenc
distribut
correspond
percentag
well
median
mean
rank
qualit
inform
show
posit
rate
number
posit
case
denomin
vi
baselin
data
analys
two
set
involv
demograph
indic
gener
situat
primari
secondari
indic
intervent
measur
data
analys
use
ttest
test
varianc
homogen
count
data
analys
use
pearson
test
rate
data
analys
use
twosampl
wilcoxon
ranksum
test
vii
efficaci
analys
quantit
variabl
comparison
group
use
repetit
measur
analysi
varianc
covari
analysi
qualit
variabl
comparison
group
use
pearson
test
centr
effect
analysi
use
cmh
test
rate
variabl
group
comparison
test
kruskalw
test
central
effect
analysi
test
cmh
test
grade
logist
regress
viii
centr
effect
analysi
gener
linear
model
glm
cochranmantelhaenszel
cmh
method
use
quantit
qualit
indic
respect
logist
regress
model
perform
evalu
correct
rate
variabl
ix
subgroup
analysi
difficult
prevent
specif
circumst
data
affect
outcom
x
safeti
analysi
pearson
test
use
compar
preval
advers
event
two
set
advers
event
occur
trial
list
describ
descript
laboratori
test
result
normalabnorm
chang
experi
well
relationship
abnorm
chang
test
drug
record
chang
also
list
describ
advers
event
refer
advers
medic
event
occur
time
patient
sign
inform
consent
form
select
trial
time
last
followup
whether
causal
relationship
incid
advers
event
studi
drug
advers
event
type
degre
time
treatment
measur
treatment
process
record
crf
relationship
advers
event
studi
drug
base
comprehens
consider
comorbid
medic
physician
decid
whether
suspend
observ
patient
followup
survey
carri
case
patient
withdrawn
advers
event
result
record
detail
appropri
time
incid
advers
event
treatment
review
comprehens
analys
determin
whether
advers
event
relat
studi
drug
advers
event
lead
discontinu
treatment
seriou
advers
event
summaris
addit
ci
advers
event
use
fisher
exact
test
calcul
fisher
exact
test
use
compar
preval
advers
event
cld
granul
oseltamivir
placebo
open
access
end
trial
trial
end
patient
recruit
patient
complet
day
trial
followup
written
inform
consent
obtain
particip
entri
studi
voluntari
particip
ensur
utmost
confidenti
inform
tender
interview
requir
trial
monitor
ethic
committe
drug
use
clinic
trial
cld
granul
oseltamivir
approv
clinic
use
potenti
safeti
hazard
ensur
studi
patient
receiv
effect
treatment
rehabilit
placebo
control
group
provid
basic
drug
trial
clinic
unit
must
compli
gcp
protocol
clinic
trial
pharmaceut
supervisori
administr
depart
occasion
conduct
audit
inspect
cooper
sponsor
send
medic
examin
moder
seriou
advers
event
report
ethic
committe
patient
develop
advers
reaction
trial
receiv
free
medic
treatment
studyrel
inform
store
secur
studi
site
particip
inform
store
lock
file
cabinet
area
limit
access
laboratori
specimen
report
data
collect
process
administr
form
identifi
code
id
identif
number
maintain
particip
confidenti
record
contain
name
person
identifi
locat
form
inform
consent
form
store
separ
studi
record
identifi
code
number
local
databas
secur
passwordprotect
access
system
form
list
logbook
appoint
book
list
link
particip
id
number
identifi
inform
store
separ
lock
file
area
limit
access
particip
studi
inform
releas
outsid
studi
without
written
permiss
particip
dissemin
trial
publicis
region
nation
confer
final
result
present
scientif
meet
publish
peerreview
journal
authorship
accord
journal
guidelin
addit
lay
summari
studi
result
circul
potenti
interest
parti
relev
necess
research
question
studi
design
develop
patient
face
document
includ
consent
form
particip
inform
sheet
symptom
diari
followup
form
promot
materi
review
member
public
public
involv
group
includ
mixtur
research
experienc
inexperienc
peopl
tri
work
patient
advocaci
group
ensur
plain
languag
summari
studi
find
share
particip
servic
user
wider
patient
group
commun
particip
research
burden
intervent
assess
comprehens
ration
way
trial
particip
inform
trial
result
directli
howev
final
result
publish
patient
inform
influenza
viru
test
result
followup
visit
direct
patient
involv
design
protocol
herbal
therapi
common
treatment
use
patient
season
influenza
china
deserv
rigor
examin
cld
one
common
antiinfluenza
drug
use
mani
area
china
herbal
remedi
found
benefit
treat
influenza
mani
pharmacolog
studi
cld
underway
howev
current
enough
clinic
evid
evalu
whether
cld
product
suitabl
talli
safe
treat
prevent
season
influenza
protocol
design
investig
object
treatment
effect
cld
previou
studi
show
compon
cld
antivir
activ
influenza
viru
especi
earli
stage
ill
accordingli
recruit
patient
within
hour
ill
onset
sinc
lack
clinic
trial
tradit
chines
herbal
medicin
tchm
effect
safeti
tchm
investig
studi
evalu
safeti
chang
liver
kidney
function
treatment
monitor
studi
divid
patient
cold
heat
tcm
syndrom
studi
whether
differ
type
diseas
geograph
differ
analys
chang
cours
diseas
investig
whether
cld
oseltamivir
differ
therapeut
effect
differ
type
diseas
accord
basic
scienc
studi
activ
ingredi
cld
also
exert
immunemodul
antiinflamm
effect
vitro
vivo
henc
evidencebas
clinic
trial
evalu
effect
cld
treat
inflamm
induc
influenza
infect
merit
studi
mainli
base
ebm
indic
use
criteria
quantifi
modern
medicin
syndrom
differenti
tcm
still
controversi
includ
select
criteria
studi
object
observ
data
syndrom
differenti
use
explor
feasibl
quantifi
tcm
symptom
accord
theori
tcm
cld
better
effect
windheat
type
cold
lack
evid
also
hope
find
whether
differ
treatment
differ
syndrom
type
influenza
besid
evalu
safeti
efficaci
howev
consid
syndrom
differenti
tcm
mostli
base
empir
medicin
lack
modern
ebm
want
evalu
safeti
effect
cld
influenza
treatment
hope
studi
chines
herbal
medicin
chines
medicin
way
method
syndrom
differenti
time
expand
explor
evidencebas
studi
tcm
syndrom
differenti
treatment
hope
tcm
theori
ebm
would
combin
reason
way
evalu
chines
herbal
medicin
would
comprehens
cld
granul
approv
overthecount
otc
drug
mani
year
drug
meet
chines
pharmacopoeia
dosag
determin
studi
accord
instruct
manual
howev
clinic
trial
evalu
efficaci
safeti
dosag
cld
treatment
influenza
shortcom
studi
placebo
contain
excipi
sucros
lactos
dextrin
theoret
placebo
effect
treat
influenza
sinc
contain
pharmaceut
ingredi
lack
data
whether
excipi
therapeut
effect
influenza
hand
set
age
rang
year
studi
even
cld
granul
oseltamivir
could
appli
age
group
includ
age
group
year
indic
cld
granul
instruct
use
children
younger
year
older
year
cld
granul
approv
otc
drug
mani
year
children
guidanc
doctor
seriou
advers
reaction
report
mani
clinic
trial
cld
children
oseltamivir
treatment
influenza
children
report
consid
set
age
rang
year
base
follow
aspect
older
peopl
varieti
accompani
diseas
increas
difficulti
risk
test
besid
issu
patient
complianc
consid
sinc
subject
studi
outpati
age
young
old
otherwis
would
hard
followup
drop
easili
moreov
children
age
year
basic
enrol
secondari
school
commun
well
doctor
chines
law
age
year
also
boundari
children
adolesc
ideal
hope
conduct
studi
among
age
group
howev
consid
limit
narrow
age
rang
year
summari
limit
clinic
research
combin
western
chines
medicin
tcm
evalu
system
evalu
efficaci
safeti
treatment
tchm
influenza
studi
combin
tradit
medicin
evalu
modern
pharmacolog
studi
becom
import
refer
futur
research
promin
featur
studi
use
ebm
better
understand
tcm
classif
treatment
characterist
tcm
base
syndrom
differenti
